• 1
    Pauly MV. Competition and new technology. Health Aff (Millwood). 2005; 24: 1523-1535.
  • 2
    Steiner CA, Bass EB, Talamini MA, Pitt HA, Steinberg EP. Surgical rates and operative mortality for open and laparoscopic cholecystectomy in Maryland. N Engl J Med. 1994; 330: 304-308.
  • 3
    Escarce JJ, Bloom BS, Hillman AL, Shea JA, Schwartz JS. Diffusion of laparoscopic cholecystectomy among general surgeons in the United States. Med Care. 1995; 33: 256-271.
  • 4
    Kolata G. Results unproven, robotic surgery wins converts. New York Times. February 14, 2010: A1.
  • 5
    Leonhardt D. Economic scene: in health reform, a cancer offers an acid test. New York Times. July 7, 2009: A14.
  • 6
    Ficarra V, Cavalleri S, Novara G, Aragona M, Artibani W. Evidence from robot-assisted laparoscopic radical prostatectomy: a systematic review. Eur Urol. 2007; 51: 45-56.
  • 7
    Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: the comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008; 48: 435-448.
  • 8
    Hu JC, Gu X, Lipsitz SR, et al. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA. 2009; 302: 1557-1564.
  • 9
    Hu JC, Wang Q, Pashos CL, Lipsitz SR, Keating NL. Utilization and outcomes of minimally invasive radical prostatectomy. J Clin Oncol. 2008; 26: 2278-2284.
  • 10
    Barbash GI, Glied SA. New technology and health care costs—the case of robot-assisted surgery. N Engl J Med. 2010; 363: 701-704.
  • 11
    Nguyen PL, Lipsitz SR, Choueiri TK, et al. Time trends in the utilization of higher-cost treatments for prostate cancer: 2002-2007 [abstract]. Paper presented at: ASCO 2010 Genitourinary Cancers Symposium; March 5-7, 2010; San Francisco, Calif. Abstract 18.
  • 12
    Wennberg JE, Birkmeyer JD, eds. The Dartmouth Atlas of Cardiovascular Health Care. Chicago, IL: American Hospital Association Press; 1999.
  • 13
    Barry MJ, Delorenzo MA, Walker-Corkery ES, Lucas FL, Wennberg DC. The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int. 2006; 98: 973-978.
  • 14
    Hudak BB, O'Donnell J, Mazyrka N. Infant sleep position: pediatricians' advice to parents. Pediatrics. 1995; 95: 55-58.
  • 15
    Weinstein JN, Lurie JD, Olson PR, Bronner K, Fisher ES. United States trends and regional variations in lumbar spine surgery: 1992-2003. Spine. 2006; 31: 2707-2714.
  • 16
    Wisconsin Department of Health Services, Division of Public Health, Office of Health Informatics. Wisconsin Cancer Incidence and Mortality, 2002-2006 (P-45328-06). Madison, WI: Wisconsin Department of Health Services, Division of Public Health; 2009.
  • 17
    Barocas DA, Salem S, Kordan Y, et al. Robotic assisted laparoscopic prostatectomy versus radical retropubic prostatectomy for clinically localized prostate cancer: comparison of short-term biochemical recurrence-free survival. J Urol. 2010; 183: 990-996.
  • 18
    Vickers AJ, Bianco FJ, Serio AM, et al. The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst. 2007; 99: 1171-1177.
  • 19
    Begg CB, Riedel ER, Bach PB, et al. Variations in morbidity after radical prostatectomy. N Engl J Med. 2002; 346: 1138-1144.
  • 20
    Weizer AZ, Ye Z, Hollingsworth JM, et al. Adoption of new technology and healthcare quality: surgical margins after robotic prostatectomy. Urology. 2007; 70: 96-100.
  • 21
    Scales JCD, Jones PJ, Eisenstein EL, Preminger GM, Albala DM. Local cost structures and the economics of robot assisted radical prostatectomy. J Urol. 2005; 174: 2323-2329.
  • 22
    Mitka M. Direct-to-consumer advertising of medical devices under scrutiny. JAMA. 2008; 300: 1985-1986.
  • 23
    Chernew ME, Jacobson PD, Hofer TP, Aaronson KD, Fendrick AM. Barriers to constraining health care cost growth. Health Aff (Millwood). 2004; 23: 122-128.
  • 24
    Luft HS, Robinson JC, Garnick DW, Maerki SC, McPhee SJ. The role of specialized clinical services in competition among hospitals. Inquiry. 1986; 23: 83-94.
  • 25
    Centers for Medicare and Medicaid Services. Decision memo for computed tomographic angiography (CAG-00385N). asp?id=206. Accessed March 12, 2008.
  • 26
    Tversky A, Kahneman D. Advances in prospect theory: cumulative representation of uncertainty. J Risk Uncertainty. 1992; 5: 297-323.
  • 27
    United States Congress. Food and Drug Administration Modernization Act of 1997. Public Law 105-115 (111 Stat 2295). Washington, DC: US Government Printing Office; 1997.
  • 28
    Dhruva SS, Bero LA, Redberg RF. Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices. JAMA. 2009; 302: 2679-2685.
  • 29
    Kramer DB, Mallis E, Zuckerman BD, Zimmerman BA, Maisel WH. Premarket clinical evaluation of novel cardiovascular devices: quality analysis of premarket clinical studies submitted to the Food and Drug Administration 2000-2007. Am J Ther. 2010; 17: 2-7.
  • 30
    Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst. 2010; 102: 950-958.
  • 31
    Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009; 302: 1202-1209.
  • 32
    Makarov DV, Yu JB, Desai RA, Penson DF, Gross CP. The association between diffusion of the surgical robot and radical prostatectomy rates. Med Care. 2011; 49: 333-339.
  • 33
    Nguyen PL, Gu X, Lipsitz SR, et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol. 2011; 29: 1517-1524.
  • 34
    Pearson SD, Bach PB. How Medicare could use comparative effectiveness research in deciding on new coverage and reimbursement. Health Aff. 2010; 29: 1796-1804.
  • 35
    Vanderbilt University. Vanderbilt wins CHOICE award for prostate cancer research. Accessed December 6, 2010.